Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $602.03 million. The enterprise value is $911.87 million.
Important Dates
The last earnings date was Tuesday, March 11, 2025, before market open.
| Earnings Date | Mar 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 66.16 million shares outstanding. The number of shares has increased by 3.03% in one year.
| Current Share Class | 66.16M |
| Shares Outstanding | 66.16M |
| Shares Change (YoY) | +3.03% |
| Shares Change (QoQ) | +0.30% |
| Owned by Insiders (%) | 2.22% |
| Owned by Institutions (%) | 33.24% |
| Float | 34.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 13.72 |
| PS Ratio | 1.02 |
| Forward PS | 1.07 |
| PB Ratio | 4.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.81 |
| P/OCF Ratio | 15.40 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 15.46, with an EV/FCF ratio of 24.13.
| EV / Earnings | n/a |
| EV / Sales | 1.59 |
| EV / EBITDA | 15.46 |
| EV / EBIT | 22.89 |
| EV / FCF | 24.13 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 1.92.
| Current Ratio | 1.31 |
| Quick Ratio | 0.80 |
| Debt / Equity | 1.92 |
| Debt / EBITDA | 5.50 |
| Debt / FCF | 9.42 |
| Interest Coverage | 1.03 |
Financial Efficiency
Return on equity (ROE) is -21.55% and return on invested capital (ROIC) is 4.21%.
| Return on Equity (ROE) | -21.55% |
| Return on Assets (ROA) | 3.24% |
| Return on Invested Capital (ROIC) | 4.21% |
| Return on Capital Employed (ROCE) | 7.70% |
| Revenue Per Employee | $616,430 |
| Profits Per Employee | -$36,067 |
| Employee Count | 930 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 2.01 |
Taxes
| Income Tax | -5.29M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +73.65% in the last 52 weeks. The beta is 0.92, so Bioventus's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | +73.65% |
| 50-Day Moving Average | 10.04 |
| 200-Day Moving Average | 9.90 |
| Relative Strength Index (RSI) | 39.95 |
| Average Volume (20 Days) | 391,689 |
Short Selling Information
The latest short interest is 811,262, so 1.23% of the outstanding shares have been sold short.
| Short Interest | 811,262 |
| Short Previous Month | 793,873 |
| Short % of Shares Out | 1.23% |
| Short % of Float | 2.35% |
| Short Ratio (days to cover) | 1.92 |
Income Statement
In the last 12 months, Bioventus had revenue of $573.28 million and -$33.54 million in losses. Loss per share was -$0.52.
| Revenue | 573.28M |
| Gross Profit | 388.23M |
| Operating Income | 39.84M |
| Pretax Income | -48.54M |
| Net Income | -33.54M |
| EBITDA | 58.98M |
| EBIT | 39.84M |
| Loss Per Share | -$0.52 |
Full Income StatementBalance Sheet
The company has $41.58 million in cash and $356.06 million in debt, giving a net cash position of -$314.47 million or -$4.75 per share.
| Cash & Cash Equivalents | 41.58M |
| Total Debt | 356.06M |
| Net Cash | -314.47M |
| Net Cash Per Share | -$4.75 |
| Equity (Book Value) | 185.60M |
| Book Value Per Share | 2.25 |
| Working Capital | 65.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $38.80 million and capital expenditures -$1.01 million, giving a free cash flow of $37.79 million.
| Operating Cash Flow | 38.80M |
| Capital Expenditures | -1.01M |
| Free Cash Flow | 37.79M |
| FCF Per Share | $0.57 |
Full Cash Flow StatementMargins
Gross margin is 67.72%, with operating and profit margins of 6.95% and -5.85%.
| Gross Margin | 67.72% |
| Operating Margin | 6.95% |
| Pretax Margin | -8.57% |
| Profit Margin | -5.85% |
| EBITDA Margin | 10.29% |
| EBIT Margin | 6.95% |
| FCF Margin | 6.59% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.03% |
| Shareholder Yield | -3.03% |
| Earnings Yield | -5.61% |
| FCF Yield | 6.33% |
Analyst Forecast
The average price target for Bioventus is $15.00, which is 64.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.00 |
| Price Target Difference | 64.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 0.95 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.95 |
| Piotroski F-Score | 6 |